TAMYRA TRICE: Open Payments
NPI 1740291483 · MILWAUKEE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,221 in 58 payments from 16 companies in 2025. Trend: 2023 $946 · 2024 $1,329 · 2025 $1,221
Food & beverage: $1,221
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $287 |
| PFIZER INC. | 6 | $175 |
| AstraZeneca Pharmaceuticals LP | 7 | $148 |
| Gilead Sciences, Inc. | 6 | $146 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $87 |
| Novo Nordisk Inc | 3 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $33 |
Products named: PREVNAR 20, CREON, Kerendia, AIRSUPRA, Ozempic, LINZESS, UBRELVY, CAPLYTA.
Industry payments across WI — which companies pay providers there.
